Spectrum Brands' Global Pet Care segment returned to growth in fiscal 2026Pet Age opened nominations for its 2027 Retailer Excellence Awards, which close January 31AAHA published parasite guidelines for veterinary teams, not retail shelf decisionsScrumpf launched air-dried goat and venison meals at Interzoo and opened UK trade orderingH&H Group's pet segment fell 13.5% in Q3 as China contraction offset North American gainsWin World launched a walk-in dog house with attached run and storage for $1,499.99SquarePet hired Rich Zanetti to cover its South Central territory after promoting the prior repPet Wellbeing Launches Liquid Ashwagandha in Separate Dog and Cat FormulasSpectrum Brands' Global Pet Care segment returned to growth in fiscal 2026Pet Age opened nominations for its 2027 Retailer Excellence Awards, which close January 31AAHA published parasite guidelines for veterinary teams, not retail shelf decisionsScrumpf launched air-dried goat and venison meals at Interzoo and opened UK trade orderingH&H Group's pet segment fell 13.5% in Q3 as China contraction offset North American gainsWin World launched a walk-in dog house with attached run and storage for $1,499.99SquarePet hired Rich Zanetti to cover its South Central territory after promoting the prior repPet Wellbeing Launches Liquid Ashwagandha in Separate Dog and Cat Formulas
Deals & M&ABy The PetRetailNews Desk3 min readJuly 29, 2026
What Do You Actually Get When PetIQ Buys a Muscle Health Brand You've Never Stocked?
PetIQ closed the MYOS acquisition. The ingredient has clinical studies. The retail proof of concept does not exist yet.
PetIQ just closed the acquisition of MYOS Corp and its Fortetropin-based muscle health products. The deal adds what PetIQ calls a clinically studied muscle health brand to its portfolio of pet medications, supplements, and wellness brands. Terms were not disclosed.
At the center of the acquisition is Fortetropin, a patented bioactive compound that the company says works by modulating myostatin, which regulates muscle mass in the body. MYOS says the ingredient can build muscle, improve mobility, and slow the rate of muscle loss that comes with aging, injury, or surgery. The company points to over a dozen clinical studies across humans and companion animals, dogs, cats, and horses, plus a patent portfolio backing the ingredient.
PetIQ CEO Camillo Pane framed the acquisition around preventive health. Pet parents are increasingly looking for solutions that support their pets' mobility, recovery, and long-term vitality, not just treatment after a problem arises, he said. He added that MYOS worked alongside veterinarians for over a decade to develop Fortetropin as a proprietary, differentiated, clinically supported ingredient.
The MYOS product lines include consumer supplements and veterinary exclusive formulations. PetIQ says the MYOS brand and Fortetropin ingredient will continue to be marketed under their existing names.
The caveat: Fortetropin has clinical studies but the retail proof of concept is not in the press release
PetIQ is betting that muscle health sits between prescription therapeutic and premium wellness, a margin zone most brands have not mapped yet. The company says it will scale MYOS with its insights-first approach, brand building capabilities, and national retail and e-commerce footprint.
But the press release does not give you where MYOS has already sold in a retail environment, or what the sell-through looked like. The clinical studies exist. The retail case study does not appear in the announcement.
That gap is the whole trade-off. If PetIQ is right and muscle health becomes a category pet owners shop for, the stores that stock it early have the advantage. If they are wrong, you committed shelf space to a science play without proof it moves at retail.
What to do if you stock senior supplements and PetIQ's rep is about to pitch you on this
Ask three questions before you say yes.
1. What does the clinical evidence actually show in terms pet owners can see? Modulates myostatin is vet language. Helps a 12-year-old Lab get up the stairs faster is what moves product. If the rep cannot translate the science into an outcome a customer would pay to solve, the SKU sits.
2. Where has this already sold in a retail environment that looks like mine? The press release says the product lines include consumer supplements and veterinary exclusive formulations, but it does not say where the consumer line has actually sold. If the only proof of concept is a vet clinic recommending it, that does not predict whether your customer picks it off the shelf.
3. What is the margin, and what is PetIQ offering to earn the space? If muscle health is a category PetIQ is building, they need distribution. Ask what the trial terms are and whether there is support behind the launch.
If you are a single-location store, this is a watch-and-see. If you are a buyer already working with PetIQ on other lines, this is the conversation to have now, before the rep moves to the next account.
Our read: PetIQ is building a portfolio around clinical claims while the category is still being defined
The acquisition tells you more about where PetIQ thinks the wellness category is going than where it is today. Muscle health as a standalone category, not folded into joint support or general senior nutrition, is not a set most stores have built yet.
PetIQ is betting it will be. And they are betting they can define the category before a larger competitor does.
Whether it works depends on whether pet parents actually start shopping for muscle health, or whether this stays a vet-recommended intervention that does not cross into retail. We would watch for proof of concept in the next year to 18 months.
If you start hearing customers ask for muscle health products by name at the register, the category is real and PetIQ got there first.
Get the next issue in your inbox. Free, weekly, no fluff.